Cargando…

Progressive Axonal Dysfunction Precedes Development of Neuropathy in Type 2 Diabetes

To evaluate the development of diabetic neuropathy, the current study examined changes in peripheral axonal function. Nerve excitability techniques were undertaken in 108 type 2 diabetic patients with nerve conduction studies (NCS), HbA(1c) levels, and total neuropathy score (TNS). Patients were cat...

Descripción completa

Detalles Bibliográficos
Autores principales: Sung, Jia-Ying, Park, Susanna B., Liu, Ya-Ting, Kwai, Natalie, Arnold, Ria, Krishnan, Arun V., Lin, Cindy S.-Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3357264/
https://www.ncbi.nlm.nih.gov/pubmed/22522615
http://dx.doi.org/10.2337/db11-1509
_version_ 1782233649364598784
author Sung, Jia-Ying
Park, Susanna B.
Liu, Ya-Ting
Kwai, Natalie
Arnold, Ria
Krishnan, Arun V.
Lin, Cindy S.-Y.
author_facet Sung, Jia-Ying
Park, Susanna B.
Liu, Ya-Ting
Kwai, Natalie
Arnold, Ria
Krishnan, Arun V.
Lin, Cindy S.-Y.
author_sort Sung, Jia-Ying
collection PubMed
description To evaluate the development of diabetic neuropathy, the current study examined changes in peripheral axonal function. Nerve excitability techniques were undertaken in 108 type 2 diabetic patients with nerve conduction studies (NCS), HbA(1c) levels, and total neuropathy score (TNS). Patients were categorized into two cohorts: patients with diabetes without neuropathy (DWN group [n = 56]) and patients with diabetes with neuropathy (DN group [n = 52]) and further into severity grade 0 (TNS 0–1 [n = 35]), grade 1 (TNS 2–8 [n = 42]), and grade 2/3 (TNS 9–24 [n = 31]). Results revealed that the DWN group had a significantly increased threshold, prolonged latency, and changes in excitability parameters compared with age-matched control subjects. Patients with neuropathy demonstrated significant alteration in recovery cycle parameters and depolarizing threshold electrotonus. Within the DWN cohort, there were significant correlations between HbA(1c) level and latency and subexcitability, whereas the estimated glomerular filtration rate correlated with superexcitability in patients with neuropathy. Furthermore, excitability parameters became progressively more abnormal with increasing clinical severity. These results suggest a spectrum of excitability abnormalities in patients with diabetes and that early axonal dysfunction may be detected prior to the development of neuropathy. As progressive changes in excitability parameters correlated to neuropathy severity, excitability testing may provide a biomarker of the early development and severity of diabetic neuropathy, providing insights into the pathophysiological mechanisms producing axonal dysfunction.
format Online
Article
Text
id pubmed-3357264
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-33572642013-06-01 Progressive Axonal Dysfunction Precedes Development of Neuropathy in Type 2 Diabetes Sung, Jia-Ying Park, Susanna B. Liu, Ya-Ting Kwai, Natalie Arnold, Ria Krishnan, Arun V. Lin, Cindy S.-Y. Diabetes Complications To evaluate the development of diabetic neuropathy, the current study examined changes in peripheral axonal function. Nerve excitability techniques were undertaken in 108 type 2 diabetic patients with nerve conduction studies (NCS), HbA(1c) levels, and total neuropathy score (TNS). Patients were categorized into two cohorts: patients with diabetes without neuropathy (DWN group [n = 56]) and patients with diabetes with neuropathy (DN group [n = 52]) and further into severity grade 0 (TNS 0–1 [n = 35]), grade 1 (TNS 2–8 [n = 42]), and grade 2/3 (TNS 9–24 [n = 31]). Results revealed that the DWN group had a significantly increased threshold, prolonged latency, and changes in excitability parameters compared with age-matched control subjects. Patients with neuropathy demonstrated significant alteration in recovery cycle parameters and depolarizing threshold electrotonus. Within the DWN cohort, there were significant correlations between HbA(1c) level and latency and subexcitability, whereas the estimated glomerular filtration rate correlated with superexcitability in patients with neuropathy. Furthermore, excitability parameters became progressively more abnormal with increasing clinical severity. These results suggest a spectrum of excitability abnormalities in patients with diabetes and that early axonal dysfunction may be detected prior to the development of neuropathy. As progressive changes in excitability parameters correlated to neuropathy severity, excitability testing may provide a biomarker of the early development and severity of diabetic neuropathy, providing insights into the pathophysiological mechanisms producing axonal dysfunction. American Diabetes Association 2012-06 2012-05-14 /pmc/articles/PMC3357264/ /pubmed/22522615 http://dx.doi.org/10.2337/db11-1509 Text en © 2012 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
spellingShingle Complications
Sung, Jia-Ying
Park, Susanna B.
Liu, Ya-Ting
Kwai, Natalie
Arnold, Ria
Krishnan, Arun V.
Lin, Cindy S.-Y.
Progressive Axonal Dysfunction Precedes Development of Neuropathy in Type 2 Diabetes
title Progressive Axonal Dysfunction Precedes Development of Neuropathy in Type 2 Diabetes
title_full Progressive Axonal Dysfunction Precedes Development of Neuropathy in Type 2 Diabetes
title_fullStr Progressive Axonal Dysfunction Precedes Development of Neuropathy in Type 2 Diabetes
title_full_unstemmed Progressive Axonal Dysfunction Precedes Development of Neuropathy in Type 2 Diabetes
title_short Progressive Axonal Dysfunction Precedes Development of Neuropathy in Type 2 Diabetes
title_sort progressive axonal dysfunction precedes development of neuropathy in type 2 diabetes
topic Complications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3357264/
https://www.ncbi.nlm.nih.gov/pubmed/22522615
http://dx.doi.org/10.2337/db11-1509
work_keys_str_mv AT sungjiaying progressiveaxonaldysfunctionprecedesdevelopmentofneuropathyintype2diabetes
AT parksusannab progressiveaxonaldysfunctionprecedesdevelopmentofneuropathyintype2diabetes
AT liuyating progressiveaxonaldysfunctionprecedesdevelopmentofneuropathyintype2diabetes
AT kwainatalie progressiveaxonaldysfunctionprecedesdevelopmentofneuropathyintype2diabetes
AT arnoldria progressiveaxonaldysfunctionprecedesdevelopmentofneuropathyintype2diabetes
AT krishnanarunv progressiveaxonaldysfunctionprecedesdevelopmentofneuropathyintype2diabetes
AT lincindysy progressiveaxonaldysfunctionprecedesdevelopmentofneuropathyintype2diabetes